ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Saad Usmani, MD, on Daratumumab as Monotherapy for Multiple Myeloma

For a heavily pretreated multiple myeloma population, daratumumab as a monotherapy showed meaningful, durable activity with deep responses and a favorable safety profile. Saad Usmani, MD, of the Levine Cancer Institute, provides the highlights of this study on the first monoclonal antibody to show promise in multiple myeloma (Abstract LBA8512).

Multiple Myeloma

Sagar Lonial, MD, and James O. Armitage, MD

Sagar Lonial, MD, and James O. Armitage, MD, on Relapsed/Refractory Multiple Myeloma: The ELOQUENT-2 Trial and a Phase II Study of Daratumumab

James O. Armitage, MD, of the University of Nebraska Medical Center, and Sagar Lonial, MD, of Emory University School of Medicine, discuss results from two important studies that tested lenalidomide/dexamethasone with or without elotuzumab and daratumumab monotherapy (Abstracts 8508 and LBA8512).

Global Cancer Care

Tony Mok, MD, and James O. Armitage, MD

Tony Mok, MD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Asian Perspective

James O. Armitage, MD, of the University of Nebraska Medical Center, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss oncology from an international point of view.

Global Cancer Care

Health-Care Policy

Lawrence N. Shulman, MD and Clifford A. Hudis, MD

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care in resource-constrained settings such as Rwanda and Haiti, and plans to conduct research in basic tumor biology of patients in these areas.

Colorectal Cancer

Dung T. Le, MD, and Axel Grothey, MD

Dung T. Le, MD, and Axel Grothey, MD, on PD-1 Blockade in Tumors With Mismatch Repair Deficiency

Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).

Sep

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Saad Usmani, MD, on Daratumumab as Monotherapy for Multiple Myeloma

Sagar Lonial, MD, and James O. Armitage, MD, on Relapsed/Refractory Multiple Myeloma: The ELOQUENT-2 Trial and a Phase II Study of Daratumumab

Tony Mok, MD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Asian Perspective

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Dung T. Le, MD, and Axel Grothey, MD, on PD-1 Blockade in Tumors With Mismatch Repair Deficiency

What Constitutes Clinical Expertise in an AI-Enabled Era

NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease

FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer

FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia

FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera